New study tests safer eczema treatment for pakistani patients
NCT ID NCT07437534
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two steroid-free ointments—crisaborole and tacrolimus—for treating mild-to-moderate eczema in 148 Pakistani patients aged 2 and older. Researchers will measure skin improvement and side effects over 8 weeks to see which works better and is safer. The goal is to provide local evidence for better eczema care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- crisaborole 2% ointment and tacrolimus 0.1% ointment
- What this could lead to
- If successful, this could help doctors choose safer, more effective eczema treatments for Pakistani patients, especially children.
- What could go wrong
- This is a small, early-phase study in one country, so results may not apply elsewhere. Both drugs have known side effects like burning or cancer risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hayatabad Medical Complex
Peshawar, KPK, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?